Overview of phase II trials of MTA in solid tumors

¹University of Pennsylvania, Philadelphia 19104, USA.

|December 22, 1999

Abstract:

MTA (LY231514, multitargeted antifolate) represents a new class of folate antimetabolites and inhibits multiple enzymes in the purine and thymidine biosynthetic pathways, including thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase. Based on the results of phase I investigation, the dose and schedule of 600 mg/m2 administered intravenously every 21 days was selected to carry into the phase II setting. A number of phase II studies are completed or ongoing in a wide range of tumor types, and encouraging results have been observed in colorectal, breast, non-small cell lung, head and neck, bladder, and cervical cancers.

Insights

Multitargeted antifolate (MTA) is a novel chemotherapy agent targeting key enzymes in cancer cell growth. Phase II studies show promising results in various cancers, including colorectal and breast cancer.

Area of Science:

Oncology
Pharmacology
Biochemistry

Background:

Multitargeted antifolate (MTA) represents a novel class of antimetabolites.
MTA inhibits crucial enzymes in purine and thymidine biosynthesis.

Purpose of the Study:

To evaluate the efficacy and safety of MTA in a phase II setting across various cancer types.
To determine the optimal dose and schedule for MTA administration.

Main Methods:

Phase I investigation established the dose and schedule.
Phase II studies are ongoing or completed in multiple tumor types.
Intravenous administration of 600 mg/m2 every 21 days was selected.

Main Results:

Encouraging results observed in colorectal, breast, non-small cell lung, head and neck, bladder, and cervical cancers.
MTA demonstrates broad-spectrum activity in diverse malignancies.

Conclusions:

MTA shows promise as a multitargeted antifolate agent in cancer therapy.
Further investigation in phase II trials supports its potential clinical utility.

Read full analysis

Related Experiment Videos

Overview of phase II trials of MTA in solid tumors

Insights

Related Concept Videos

Evidence of Higgs Boson Inclusive Production at High Transverse Momentum Decaying to a Pair of b-Quarks with the ATLAS Detector.

Combination of Measurements of CP Properties of Higgs Boson Interactions with Vector Bosons Using Proton-Proton Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Immunohistological Evaluation of Peri-Implant Soft Tissue Grafting Using a Porcine Dermal Matrix-A Human Histological Study.

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13 TeV with the ATLAS Detector.

Integrating patient-reported outcomes into explainable machine learning models for long-term survival prediction in TKI-treated metastatic renal cell carcinoma.

Tumour immunotherapy in solid and hematologic malignancies: Progress, challenges, and a practical framework.

Single-cell sequencing in pan-cancer research: Decoding heterogeneity, tumor microenvironment, and clinical translation.

Atezolizumab, lurbinectedin, tarlatamab, and FOLFIRNOX in a patient with metastatic small cell carcinoma of the anal canal: A case report and review of the literature.

Uncovering an uncommon diagnosis: Encapsulated papillary carcinoma of the male breast in a Jordanian patient-A case report.

Silver nanoparticles in tumor microenvironment modulation: Mechanistic insights, preclinical evidence, and translational challenges.

Related Experiment Videos

Overview of phase II trials of MTA in solid tumors

Abstract:

Insights

Related Concept Videos

Related Articles